Baxter International Inc. (BAX) Balance Sheet

The decline in both assets and liabilities points to portfolio divestitures and the planned Renal Care separation rather than operating earnings accumulation. Equity has moved from $7.9B to $6.5B over the same window, which suggests the reduction has not been fully offset by retained earnings. The trajectory therefore reads as a structural transition whose durability depends on completing the separation without impairing the remaining franchise.

The improvement in leverage is largely a function of debt paydown funded by asset reduction, which may limit how much of the ratio change reflects sustained earnings power. Net debt remains roughly $6.8B against a cash balance near $2.0B, implying refinancing needs will continue to shape capital allocation. Investors should monitor whether further deleveraging can proceed without sacrificing the cash generation that services the remaining obligations.

The reduction in goodwill tracks the divestiture activity rather than organic asset quality improvement, which means the remaining intangible balance reflects acquisitions such as Hillrom that have yet to demonstrate consistent margin returns. Net PP&E has held near $3.1B to $3.2B, suggesting a relatively stable manufacturing footprint. The concentration of value in goodwill warrants close monitoring for impairment testing, particularly given the negative operating margins reported in recent periods.

The current ratio has moved between 1.36 and 2.31 over the period, indicating that near-term liquidity is serviceable but sensitive to working capital swings. Cash has remained in a narrow $1.4B to $2.3B band despite large debt reductions, which suggests much of the proceeds have been directed to repayment. This leaves limited room to absorb a shock such as a delayed divestiture closing or an adverse regulatory event.